Skip to main content

Table 3 Clinical characteristics of the study population

From: A prospective, single-centre, single-arm, open label study of the long term use of a gonadotropin releasing hormone agonist (Triptorelin SR, 11.25 mg) in combination with Tibolone add-back therapy in the management of chronic cyclical pelvic pain

Predominant symptom

Percentage

Severe dysmenorrhea

85.2%

Moderate dysmenorrhea

14.8%

Severe dyspareunia

18.5%

Moderate dyspareunia

29.6%

Mild dyspareunia

3.7%

Back to article page

Reproductive Biology and Endocrinology

ISSN: 1477-7827

Contact us